Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction

被引：53

作者：

Gutstein, D. E. ^{[1
]}

Krishna, R. ^{[1
]}

Johns, D. ^{[1
]}

Surks, H. K. ^{[1
]}

Dansky, H. M. ^{[1
]}

Shah, S. ^{[1
]}

Mitchel, Y. B. ^{[1
]}

Arena, J. ^{[1
]}

Wagner, J. A. ^{[1
]}

机构：

[1] Merck Sharp & Dohme Corp, Rahway, NJ USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2012年 / 91卷 / 01期

关键词：

ESTER TRANSFER PROTEIN; HIGH-DENSITY-LIPOPROTEIN; CORONARY-HEART-DISEASE; REVERSE CHOLESTEROL TRANSPORT; TYPE-2; DIABETES-MELLITUS; BLOOD-PRESSURE; HEALTHY-SUBJECTS; DOUBLE-BLIND; LIPID-LEVELS; IN-VIVO;

D O I：

10.1038/clpt.2011.271

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

Cholesteryl ester transfer protein (CETP) inhibition is a promising experimental strategy to raise high-density lipoprotein cholesterol (HDL-C) and reduce cardiovascular risk. This review focuses on the highly selective and potent CETP inhibitor anacetrapib and discusses the available preclinical and clinical information pertaining to it. We also describe strategies to target HDL-C, discuss the mechanism underlying CETP inhibition and its effects on lipid biology, and give an overview of other CETP inhibitors that are currently in development.

引用

页码：109 / 122

页数：14

共 92 条

[1]

[Anonymous], TREATMENT HDL REDUCE

[2]

[Anonymous], 2007, HEART DIS STROK STAT

[3]

[Anonymous], STUDY RO4607381 STAB

[4]

[Anonymous], 2011, N ENGL J MED

[5]

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].

Baigent, C ;

Keech, A ;

Kearney, PM ;

Blackwell, L ;

Buck, G ;

Pollicino, C ;

Kirby, A ;

Sourjina, T ;

Peto, R ;

Collins, R ;

Simes, J .

LANCET, 2005, 366 (9493) :1267-1278

[6]

Effects of torcetrapib in patients at high risk for coronary events [J].

Barter, Philip J. ;

Caulfield, Mark ;

Eriksson, Mats ;

Grundy, Scott M. ;

Kastelein, John J. P. ;

Komajda, Michel ;

Lopez-Sendon, Jose ;

Mosca, Lori ;

Tardif, Jean-Claude ;

Waters, David D. ;

Shear, Charles L. ;

Revkin, James H. ;

Buhr, Kevin A. ;

Fisher, Marian R. ;

Tall, Alan R. ;

Brewer, Bryan .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21) :2109-2122

[7]

BARTER PJ, 1982, BIOCHEM J, V208, P1

[8]

Cholesteryl ester transfer protein - A novel target for raising HDL and inhibiting atherosclerosis [J].

Barter, PJ ;

Brewer, HB ;

Chapman, MJ ;

Hennekens, CH ;

Rader, DJ ;

Tall, AR .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (02) :160-167

[9]

Effects of CP-532,623 and Torcetrapib, Cholesteryl Ester Transfer Protein Inhibitors, on Arterial Blood Pressure [J].

Blasi, Eileen ;

Bamberger, Mark ;

Knight, Delvin ;

Engwall, Mike ;

Wolk, Robert ;

Winter, Steven ;

Betts, Allison ;

John-Baptiste, Annette ;

Keiser, Joan .

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2009, 53 (06) :507-516

[10]

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients [J].

Bloomfield, Daniel ;

Carlson, Gary L. ;

Sapre, Aditi ;

Tribble, Diane ;

McKenney, James M. ;

Littlejohn, Thomas W., III ;

Sisk, Christine McCrary ;

Mitchel, Yale ;

Pasternak, Richard C. .

AMERICAN HEART JOURNAL, 2009, 157 (02) :352-U20

← 1 2 3 4 5 6 7 8 9 10 →